Literature DB >> 20099978

Platelet activation in patients with advanced gastric cancer.

J Osada1, M Rusak, Z Kamocki, M I Dabrowska, B Kedra.   

Abstract

The aim of this study was to evaluate platelet activation in gastric cancer patients with regard to histopathological classification and the presence of distant metastases, by using platelet morphological parameters: MPV, L-PLT, MPC, as well as quantitative evaluation of surface receptor expression: CD41a, CD61, CD42b, CD62P, by flow cytometry at the resting state and after TRAP activation. In gastric cancer patients higher values of MPV and LP, as well as decreased MPC values were determined. Quantitative evaluation of surface antigen expression also revealed higher number of CD41a, CD61 and CD62P molecules, as compared with the platelets in the control group. Significant decrease of CD42b molecules' number after TRAP incubation, and the increased CD41a, CD61 and CD62P expression also point to the retained reactivation capacity of platelets. Good correlation between morphological parameters and the number of CD62P molecules indicates the usefulness of routine tests in evaluation of platelet activation.

Entities:  

Mesh:

Year:  2010        PMID: 20099978     DOI: 10.4149/neo_2010_02_145

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  24 in total

1.  Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity.

Authors:  Sylvia S W Ng; Hong Zhang; Lisa Wang; Deborah Citrin; Laura A Dawson
Journal:  NPJ Precis Oncol       Date:  2020-07-14

2.  Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

Authors:  Jianping Huang; Caroline Jochems; Tara Talaie; Austin Anderson; Alessandra Jales; Kwong Y Tsang; Ravi A Madan; James L Gulley; Jeffrey Schlom
Journal:  Blood       Date:  2012-08-28       Impact factor: 22.113

3.  Assessment of platelet activation and phagocytic activity in gastric cancer patients.

Authors:  Joanna Matowicka-Karna; Zbigniew Kamocki; Halina Kemona
Journal:  World J Gastrointest Pathophysiol       Date:  2013-02-15

4.  Performance of Current Thromboembolism Risk Assessment Tools in Patients With Gastric Cancer and Validity After First Treatment.

Authors:  Harry E Fuentes; L H Paz; Y Wang; D M Oramas; C R Simons; A J Tafur
Journal:  Clin Appl Thromb Hemost       Date:  2017-09-08       Impact factor: 2.389

5.  Prognostic value of hematological parameters in patients undergoing esophagectomy for esophageal squamous cell carcinoma.

Authors:  Noriyuki Hirahara; Takeshi Matsubara; Daisuke Kawahara; Yoko Mizota; Shuichi Ishibashi; Yoshitsugu Tajima
Journal:  Int J Clin Oncol       Date:  2016-05-06       Impact factor: 3.402

6.  Platelets and inflammatory markers in patients with gastric cancer.

Authors:  Joanna Matowicka-Karna; Zbigniew Kamocki; Beata Polińska; Joanna Osada; Halina Kemona
Journal:  Clin Dev Immunol       Date:  2013-03-10

7.  The role of soluble CD40L in immunosuppression.

Authors:  Jeffrey Schlom; Caroline Jochems; James L Gulley; Jianping Huang
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

8.  Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.

Authors:  Hye Won Chung; Jong-Baeck Lim
Journal:  J Transl Med       Date:  2014-04-21       Impact factor: 5.531

9.  Elucidating the correlation between treatment with tyrosine kinase inhibitors and mean platelet volume in patients with metastatic renal cell cancer.

Authors:  Seyda Gunduz; Hasan Mutlu; Mukremin Uysal; Hasan Senol Coskun; Hakan Bozcuk
Journal:  Oncol Lett       Date:  2014-09-03       Impact factor: 2.967

10.  Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients.

Authors:  Fan Zhang; Zhaoli Chen; Pan Wang; Xueda Hu; Yibo Gao; Jie He
Journal:  Tumour Biol       Date:  2016-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.